Page 696 - Read Online

Girotti et al. J Cancer Metastasis Treat 2020;6:52 I http://dx.doi.org/10.20517/2394-4722.2020.107 Page 13 of 15

Authors’ contributions
Wrote the manuscript and secured funding for the ALA-PDT/iNOS/NO studies carried out in his
laboratory: Girotti AW
Planned and carried out most of the experiments represented in Figures 2-5, and made helpful suggestions
about the manuscript: Fahey JM
Secured funding for the PDT-bystander studies and offered helpful suggestions about the manuscript:
Korytowski W.

Financial support and sponsorship
The research of two authors (Albert W. Girotti and Witold Korytowski) was supported by the following
grants: USPHS Grant CA70823 from the National Cancer Institute, BSC Grant FP12605, and Rock River
Grant FP14869 from the MCW Cancer Center (to Albert W. Girotti); NCN Grant 2017/27/B/NZ5/02620 (to
Witold Korytowski).

Conflicts of interest
The authors have no conflicts of interest to declare.

Consent for publication
Not applicable

Ethics approval
Not applicable

Copyright
© The Author(s) 2020.

REFERENCES
1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Neuropathol 2007;114:97-
109.
2. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. The Lancet 2003;361:323-31.
3. Wen PY, Kesari S. Malignant gliomas in adults. New Engl J Med 2008;359:492-507.
4. Stewart DJ, Molep JM, Eapen L, et al. Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological
considerations and results of early studies. Int. J Radiat Oncol Biol Phys 1994;28:531-42.
5. Yang LJ, Zhou CF, Lin ZX. Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. Cancer
Investig 2014;32:31-6.
6. Miranda A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part 1: molecular pathways and novel
treatment approaches. Int J Pharm 2017;531:372-88.
7. Bouzinab K, Summers H, Zhang J, et al. In serach of effective therapies to overcome resistance to temozolomide in brain tumors. Cancer
Drug Resist 2019;2:1018-31.
8. Quirk BJ, Brandal G. Donlon S, et al. Photodynamic therapy (PDT) for brain tumors: where do we stand? Photodiagn Photodyn Ther
2015; 12:530-44.
9. Bechet D, Mordon SR, Guillemin F, Barberi-Heyob MA, Photodynamic therapy of malignant brain tumours: a complementary approach
to conventional therapies. Cancer Treat Rev 2014;40:229-41.
10. Cramer SW, Chen CC. Photodynamic therapy for the treatment of glioblastoma. Front Surg 2020;6:81.
11. Casas A, Perotti C, Ortel B, et al. Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving
cells. Int J Oncol 2006;29:397-405.
12. Casas A, Di Venosa, G, Hasan T, Batlle A. Mechanisms of resistance to photodynamic therapy. Curr Med Chem 2011;18:2486-515.
13. Girotti AW. Upregulation of nitric oxide in tumor cells as a negative adaptation to photodynamic therapy. Lasers in Surg Med
2018;50:590-8.
14. Fahey JM, Girotti AW. Nitric oxide antagonism to anti-glioblastoma photodynamic therapy: mitigation by inhibitors of nitric oxide
generation. Cancers 2019;11:231.
15. Thomas DD, Liu X, Kantrow SP, Lancaster JR Jr. The biological lifetime of nitric oxide: implications for the perivascular dynamics of
NO and O2. Proc Natl Acad Sci U S A 2001;98:355-60.
16. Gantner BN, LaFond KM, Bonini MG. Nitric oxide in cellular adaptation and disease. Redox Biol 2020;34:101550.